Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Yamaguchi, Ryuji ^a,d   Janssen, Edith ^b   Perkins, Guy ^c   Ellisman, Mark ^c   Kitada, Shinichi ^a   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; D 3179; DEOXYGLUCOSE; NAVITOCLAX; UNCLASSIFIED DRUG; ABT-737; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; CYTOCHROME C; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN BCL 2; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; MITOCHONDRION; MONOTHERAPY; MOUSE; NONHUMAN; PROSTATE CANCER; TISSUE SPECIFICITY; TUMOR XENOGRAFT; ANIMAL; CELL STRAIN HEPG2; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; HELA CELL; METABOLISM; MOUSE MUTANT; NEOPLASM; NUDE MOUSE; PATHOLOGY; SURVIVAL; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALIA; MUS;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOCHROMES C; DEOXYGLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HEP G2 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; MITOCHONDRIA; NEOPLASMS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; SURVIVAL ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052886169     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024102     Document Type: Article

References (72)

1. Pelicano H, Martin DS, Xu RH, Huang P, (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646.
2. Caraco C, Aloj L, Chen LY, Chou JY, Eckelman WC, (2000) Cellular release of [18F]2-fluoro-2-deoxyglucose as a function of the glucose-6-phosphatase enzyme system. J Biol Chem 275: 18489-18494.
3. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, et al. (2004) 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64: 31-34.
4. Dearling JL, Qureshi U, Begent RH, Pedley RB, (2007) Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy. Clin Cancer Res 13: 1903-1910.
5. Zhong D, Liu X, Schafer-Hales K, Marcus AI, Khuri FR, et al. (2008) 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMP-activated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Ther 7: 809-817.
6. Zhong D, Xiong L, Liu T, Liu X, Chen J, et al. (2009) The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem 284: 23225-23233.
7. Hockenbery DM, (2010) Targeting mitochondria for cancer therapy. Environ Mol Mutagen 51: 476-489.
8. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
9. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
10. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, et al. (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68: 2321-2328.
11. Salvesen GS, Riedl SJ, (2008) Caspase mechanisms. Adv Exp Med Biol 615: 13-23.
12. Green DR, Amarante-Mendes GP, (1998) The point of no return: mitochondria, caspases, and the commitment to cell death. Results Probl Cell Differ 24: 45-61.
13. Galluzzi L, Kroemer G, (2007) Mitochondrial apoptosis without VDAC. Nat Cell Biol 9: 487-489.
14. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, et al. (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434: 658-662.
15. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, et al. (2005) Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434: 652-658.
16. Yamaguchi R, Perkins G, (2009) Dynamics of mitochondrial structure during apoptosis and the enigma of Opa1. Biochim Biophys Acta 1787: 963-972.
17. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, et al. (2008) Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135: 1074-1084.
18. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, et al. (2002) Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111: 331-342.
19. Schafer B, Quispe J, Choudhary V, Chipuk JE, Ajero TG, et al. (2009) Mitochondrial outer membrane proteins assist Bid in Bax-mediated lipidic pore formation. Mol Biol Cell 20: 2276-2285.
20. Willis SN, Chen L, Dewson G, Wei A, Naik E, et al. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305.
21. Ren D, Tu HC, Kim H, Wang GX, Bean GR, et al. (2010) BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 330: 1390-1393.
22. Chipuk JE, Green DR, (2009) PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle 8: 2692-2696.
23. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
24. Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, et al. (2011) BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem 286: 13905-13913.
25. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399.
26. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, et al. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388.
27. Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, et al. (2006) Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 8: 725-732.
28. Chen TR, (1993) Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. Cytogenet Cell Genet 62: 183-184.
29. van Bokhoven A, Varella-Garcia M, Korch C, Hessels D, Miller GJ, (2001) Widely used prostate carcinoma cell lines share common origins. Prostate 47: 36-51.
30. Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, et al. (2008) A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 15: 820-830.
31. Yamaguchi R, Lartigue L, Perkins G, Scott RT, Dixit A, et al. (2008) Opa1-mediated cristae opening is Bax/Bak and BH3 dependent, required for apoptosis, and independent of Bak oligomerization. Mol Cell 31: 557-569.
32. Berman SB, Chen YB, Qi B, McCaffery JM, Rucker EB 3rd, et al. (2009) Bcl-x L increases mitochondrial fission, fusion, and biomass in neurons. J Cell Biol 184: 707-719.
33. Arnoult D, (2007) Mitochondrial fragmentation in apoptosis. Trends Cell Biol 17: 6-12.
34. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, et al. (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687.
35. Bossy-Wetzel E, Newmeyer DD, Green DR, (1998) Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 17: 37-49.
36. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR, (2000) The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2: 156-162.
37. Slee EA, Keogh SA, Martin SJ, (2000) Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ 7: 556-565.
38. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dorken B, et al. (2003) Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 22: 2236-2247.
39. Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, et al. (2010) Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29: 1641-1652.
40. Caro-Maldonado A, Tait SW, Ramirez-Peinado S, Ricci JE, Fabregat I, et al. (2010) Glucose deprivation induces an atypical form of apoptosis mediated by caspase-8 in Bax-, Bak-deficient cells. Cell Death Differ 17: 1335-1344.
41. Saikumar P, Dong Z, Patel Y, Hall K, Hopfer U, et al. (1998) Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene 17: 3401-3415.
42. Owens TW, Valentijn AJ, Upton JP, Keeble J, Zhang L, et al. (2009) Apoptosis commitment and activation of mitochondrial Bax during anoikis is regulated by p38MAPK. Cell Death Differ 16: 1551-1562.
43. Karbowski M, Norris KL, Cleland MM, Jeong SY, Youle RJ, (2006) Role of Bax and Bak in mitochondrial morphogenesis. Nature 443: 658-662.
44. Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodovar C, Palacios C, Lopez-Rivas A, (2003) Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem 278: 12759-12768.
45. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, et al. (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26: 3972-3979.
46. Hauck P, Chao BH, Litz J, Krystal GW, (2009) Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 8: 883-892.
47. Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, et al. (2002) Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 1: 65-69.
48. Kohno T, Morishita K, Takano H, Shapiro DN, Yokota J, (1994) Homozygous deletion at chromosome 2q33 in human small-cell lung carcinoma identified by arbitrarily primed PCR genomic fingerprinting. Oncogene 9: 103-108.
49. Gridley DS, Nutter RL, Mantik DW, Slater JM, (1985) Hyperthermia and radiation in vivo: effect of 2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 11: 567-574.
50. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, et al. (2008) Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60: 988-1009.
51. Wojciechowski S, Tripathi P, Bourdeau T, Acero L, Grimes HL, et al. (2007) Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J Exp Med 204: 1665-1675.
52. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, et al. (2007) Programmed anuclear cell death delimits platelet life span. Cell 128: 1173-1186.
53. Pan Y, Lui WO, Nupponen N, Larsson C, Isola J, et al. (2001) 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. Genes Chromosomes Cancer 30: 187-195.
54. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, et al. (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-549.
55. Hyer ML, Shi R, Krajewska M, Meyer C, Lebedeva IV, et al. (2008) Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer. Cancer Res 68: 2927-2933.
56. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E, (2007) Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) 232: 227-234.
57. Xiao D, Lew KL, Kim YA, Zeng Y, Hahm ER, et al. (2006) Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction. Clin Cancer Res 12: 6836-6843.
58. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, et al. (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520.
59. Srivastava SK, Xiao D, Lew KL, Hershberger P, Kokkinakis DM, et al. (2003) Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis 24: 1665-1670.
60. Weinstein IB, Begemann M, Zhou P, Han EK, Sgambato A, et al. (1997) Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 3: 2696-2702.
61. Weinstein IB, Joe A, (2008) Oncogene addiction. Cancer Res 68: 3077-3080; discussion 3080.
62. Weinstein IB, Joe AK, (2006) Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457.
63. Sawyers C, (2004) Targeted cancer therapy. Nature 432: 294-297.
64. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042.
65. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645-652.
66. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
67. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
68. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
69. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, et al. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698.
70. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, et al. (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22: 1200-1206.
71. Jonkers J, Berns A, (2004) Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6: 535-538.
72. Stratton MR, Campbell PJ, Futreal PA, (2009) The cancer genome. Nature 458: 719-724.